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Abstract 
The dependence of mankind for therapeutic applications on plants dates back to the start of the human 
race. Natural remedies from ethnobotanicals are found to be safe and cost effective. Due to the poor 
pharmacokinetic profiles and toxicity problems many synthetic drugs often fails to enter the market thus, 
the pharmacologically active compounds from plants continued to provide an important source of novel 
drug leads. The early inclusion of pharmacokinetics consideration in the drug discovery process using in 
silico methods is becoming popular due to improved generation of software’s. The problems with 
conventional method required time-consuming multi-step processes against a battery of in vivo biological 
screening and high cost thus, In silico prediction of the pharmacokinetic parameters, biological properties 
and toxicity due to advent of chemo-informatics tools, has reduced the cost dramatically and early 
application in drug design are realized. The present investigation deals with computational evaluation of 
six isolated phytocompounds from Flacourtia indica for their pharmacological potential and biological 
activities. These compounds were evaluated for drug likeness properties, bioactivity score, ADME/T 
profiles, and health affects by using various bioinformatics tools. The result indicated that all the six 
compounds analyzed were non mutagens, non-carcinogens and having good drug-likeness properties 
were seen. The ADMET parameters and probability of health effects were analyzed by admet SAR and 
ACD/I-Lab online tools respectively and results shows the ADMET and probability of health effects 
values are also in satisfying ranges. Pharmacological activities of these compounds were predicted 
individually using PASS server many different pharmacological activities and mechanisms of action 
shown by these compounds were reported. The results of our analysis clearly depict that all six 
phytocompounds were having good pharmacokinetic profiles with numerous biological activities. These 
compounds can be further studied in vitro and in vivo for the discovery of novel preventive and 
therapeutic drug. 
 
Keywords: Flacourtia indica, phytopharmaceuticals, ADMET, PASS, in silico, pharmacokinetics, drug 
discovery 
 
Introduction 
Plants have been exploited over the millennia for human welfare in the promotion of health 
and as therapeutic drugs. Most of the developing countries such as China, India, Sri Lanka and 
a few others endowed with vast resources of medicinal and aromatic plants. Plants being rich 
sources of secondary metabolites such as alkaloids, terpenoids, triterpenies, flavanoids, 
tannins, and phenolic compounds etc. which are responsible for various biological activities 
have been used as treatment for various ailments (de-Fathima et al., 2006) [7]. In the later 
mediaeval period, Islamic part of the world has flourished the herbalism (David taylor, 2014) 
and Arab’s were encouraged to use plants and fruits as nutraceuticals, the holy Quran mentions 
many plants as nutraceuticals so that the mankind can enjoy and benefit from their nutritional 
and health values. Among some of the ethnobotanicals mentioned in the holy Quran and 
Hadith by the Holy Prophet Mohammed ﷺ (Peace Be Upon Him) are Sweet flag, Myrrh, 
Memcylon (Tintura), Barley, Sweet basil, Pomegranate, grapes, citrus, melon, squash, Figs, 
date palm, honey, olive oil, and black seeds etc,.(Rahman et al., 2008; Ahmad et al., 2009) [19, 
1]. The statement of Holy Prophet Mohammed ﷺ (Peace Be upon Him) that “there is no 
disease that Allah has created, except that He also has created its treatment” encouraged 
Mankind to engage in medical research and seek out a cure for every disease known to them 
(Ahmed and Hasan, 2015). Medicinal plants, the backbone of traditional medicine with 
excessive pharmacological studies are the potential source of lead compounds in drug 
development (Mathew et al., 2016) [15]. Modern pharmacopoeia still contains at least 25% 
drugs derived from plants (De Silva, 1997) [8]. Since many synthetic drugs often fail to enter  
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the market as a result of poor pharmacokinetic and 
pharmacodynamics profiles (Ntie-Kang, 2013) [17], therefore 
phytopharmaceuticals are preferred since Plants have been 
evolved through biological validation and therefore induce 
less toxicity and side effects as compared to synthetic drugs 
(Mathew et al., 2016) [15]. The use of plants in the control and 
treatment of diseases in recent years has gained considerable 
importance and major sources of biologically active and high 
pharmacological active compounds are from plants and fruits 
(WHO Report, 2002) [22]. 
The objective of drug design is to find a chemical compound 
that can fit to a specific cavity called binding pocket cleft on a 
protein target both geometrically and chemically. After 
passing the animal tests and human clinical trials, this 
compound becomes a drug available in market to patients. 
The conventional drug design methods include random 
screening of chemicals found in nature or synthesized in 
laboratories. The problems with conventional method 
required time-consuming multi-step processes against a 
battery of in vivo biological screening and high cost. Modern 
approach including structure-based drug design with the help 
of informatics technologies and computational methods has 
speeded up the drug discovery process in an efficient manner. 
Remarkable progress has been made during the past five years 
in almost all the areas concerned with drug design and 
discovery. An improved generation of software’s with easy 
operation and superior computational tools to generate 
chemically stable and worthy compounds with refinement 
capability has been developed. These tools can tap into 
cheminformation to shorten the cycle of drug discovery, and 
thus make drug discovery in more efficiency, cost 
effectiveness, time saving, and will provide strategies for 
combination therapy in addition to overcoming toxic side 
effect (Mandal et al., 2009; Baldi, 2010; Sharma and Sarkar, 
2013) [14, 5, 21]. 
The present investigation aimed to assess the 
pharmacokinetics, pharmacological properties and biological 
activities of the isolated phytocompounds from Flacourtia 
indica (BURM.F.) Merr. By computational approach. 
Flacourtia indica (Burm.f.) Merr, belonging to the family 
Flacourtiaceae, is a small deciduous thorny shrub indigenous 
to the Indian Peninsula. Flacourtia indica is very popular and 
used as folklore medicine to treat various diseases, fruits are 
used in the treatment of jaundice and enlarged spleen, seeds 
are used as rheumatic pain, bark is applied to the body duting 
intermittent fever and root is used in the nephritic colic 
(Eramma and Gayathri, 2013; Sashidhara et al., 2013) [9, 20] 
isolated and purified six phytocompounds viz.,”(1) 2-(2-
benzoyl-b-D-glucopyranosyloxy)-7-(1a,2a,6a-trihydroxy-3-
oxocyclohex-4-enoyl)-5-hydroxy benzyl alcohol, (2) 
poliothrysoside, (3) catechin-[5,6-e]-4b-(3,4-dihydroxy 
phenyl)dihydro-2(3H)-pyranone, (4) 2-(6-benzoyl-b-D-
glucopyranosyloxy)-7-(1a,2a,6a-trihydroxy-3-oxocyclo hex-
4-enoyl)-5-hydroxybenzyl alcohol (5), chrysoeriol-7-O-b-D-
glucopyranoside and (6) mururin A” by applying series of 
chromatographic techniques and Experimentally reported that 
Compound 6 significantly inhibited the in vitro growth of 
both a chloroquine-sensitive(3D7) and a chloroquine-resistant 
(K1) strain of Plasmodium falciparum (Sashidhara et al., 
2013) [20]. 
 
Methods and Implications 
Preparation of phyto-ligands 
The six phytocompounds isolated from Flacourtia indica 
(Sashidhara et al., 2013) [20] viz., “(1) 2-(2-benzoyl-b-D-
glucopyranosyloxy)-7-(1a,2a,6a-trihydroxy-3-oxocyclohex-4-
enoyl)-5-hydrox -ybenzylalcohol, (2) poliothrysoside, (3) 
catechin-[5,6-e]-4b-(3,4- dihydro xyphenyl) dihydro-2(3H)-
pyranone, (4) 2-(6-benzoyl-b-D-glucopyranosyloxy)-7-
(1a,2a,6a-trihydroxy-3-oxocyclo hex-4-enoyl)-5-
hydroxybenzyl alcohol (5), chrysoeriol-7-O-b-D-
glucopyranoside and (6) mururin A” were tested for their 
pharmacological Potential and biological activity for use as 
promising therapeutic compounds. The 2D and 3D structures 
of these isolated phytocompounds were obtained from online 
server’s viz., PubChem (http://pubchem.ncbi.nlm.nih.gov/) 
and ChemSpider (http://www.chemspider.com/) and each 
chemical compound was constructed using ACD/ Chemsketch 
bioinformatics tool and saved in the ‘.mol’ format. 
 
In silico pharmacokinetics analysis 
(a) Prediction Drug-likeness properties 
Drug-likeness of a chemical compound is equilibrium 
amongst the molecular properties of a compound which 
directly affects biological activity, pharmacodynamics and 
pharmacokinetics of a drug in human body (Menezes et al., 
2011) [16]. The “drug-likeness” test was carried out using 
Lipinski’s “Rule of Five”, ro5 (Lipinski et al., 1997). The 
distributions of the compound molecular weights (MW), 
calculated lipophilicity (logp), number of hydrogen bond 
acceptors (HBA) and number of hydrogen bond donors 
(HBD) were used to assess the “drug-likeness” of Compounds 
(Ntie-Kang F, 2013) [17]. Depending on these four molecular 
descriptors, the approach generates a vigilant about apparent 
absorption trouble; the rule states that most “druglike” 
molecules must have log P≤ 5, molecular weight ≤ 500, 
number of hydrogen bond acceptors ≤ 10, and number of 
hydrogen bond donors ≤ 5. Molecules violating more than one 
of these rules may have problems with oral bioavailability 
(Paramashivam et al., 2015) [18]. 
 
(b) Prediction of bioactivity scores of Phytocompounds 
Molinspiration 
Molinspiration tool was used In order to predict bioactivity 
score, Molinspiration is a free on-line cheminformatics 
services for calculation of important molecular properties as 
well as prediction of bioactivity score for the most important 
phytoconstituents drug targets such as GPCR ligand, Ion 
channel modulator, Kinase inhibitor, Nuclear receptor ligand, 
Protease inhibitor, Protease inhibitor and Enzyme inhibitor 
(Balasundaram et al., 2016 ) [4]. 
 
(c) ADME/Tox Predictions by AdmetSAR 
Pharmacokinetics (PK) plays a key role throughout 
pharmaceutical research and development (Alavijeh et al., 
2005) [3]. ADMET is an abbreviation in pharmacokinetics for 
“absorption, distribution, metabolism, excretion and 
Toxicity.” A set of algorithms are involved in predicting the 
pharmacological activity of a molecule as a prospective drug 
(Lydia and Sudarsanam, 2015) [13]. The pharmacokinetic 
properties such as Absorption, Distribution, Metabolism, 
Excretion and the Toxicity of the compounds can be predicted 
using admet SAR (http:// www.admetexp.org) online 
database. It provides the latest and most comprehensive 
manually curated data for diverse chemicals associated with 
known ADMET profiles. 
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(d) Computation Lethal Dose 50 and probability of health 
effects using ACD/I-Lab 
ACD/I labs is a free online server which consist of a set of 
molecular and ADMET descriptors. The probability of health 
effects and physicochemical properties was predicted using 
lethal dose50 (LD50) value. The comparative analysis of ligand 
molecules LD50 values were studied in mouse and rat by intra 
peritoneal, oral, intravenous, subcutaneous and the probability 
of toxic health effects were checked in blood, cardiovascular 
system, gastro intestinal system, kidney, liver, and lung 
tissues. 
 
(e) Predictions Biological activity by PASS Server 
PASS (Predicted Activity Spectrum for Substances) server 
(http://195.178.207.233/PASS/), this server predicted activity 
spectrum of a chemical compound as Pa (probable activity) 
and Pi (probable inactivity). The set of pharmacological 
effects, mechanisms of action, and specific toxicities, that 
might be exhibited by a particular compound in its interaction 
with biological entities, and which is predicted by PASS 
(Paramashivam et al., 2015) [18], Prediction of this spectrum 
by PASS was based on structural activity relationship (SAR) 
analysis of the training set containing 205,000 plus 
compounds having more than 3750 kinds of Pharmacological 
effects and biological activities (Goel et al., 2011) [10]. The 
compounds showing higher Pa value than Pi are the only 
constituents considered as possible for a particular 
pharmacological activity (Khurana et al., 2011; Goel et al., 
2011) [11, 10]. 
 
Results and Discussion 
Plants belonging to family Flacourtiaceae are well known for 
their biological and ethnomedicinal properties and are used as 
folklore medicine in the treatment of various ailments in 
India. The structures of the six isolated compounds were 
retrieved from pubchem and chemspider servers which are 
represented in table 1. pharmacokinetic and QSAR properties 
of the compounds were checked for their drug likeness, drug 
score, bioactivity score, ADME/T profile, and health affect by 
using various software’s mentioned in Section 2. The drug 
likeliness and drug score of the compounds were predicted by 
Lipinski’s “rule of five” and the results are depicted in Table. 
2 and graphical representation of drug likeness score was 
shown in the figure (fig.1-fig.6).Out of six phytocompounds, 
after computation it was found that compound 2 and 6 are 
significantly follows the Ro5 and other compounds violates 
one or two parameters viz. acceptable. The drug likeness 
score of all the compounds are in acceptable ranges but 
compound 3, 5 and 6 has the highest score when compare to 
others.  
The bioactivity score of the compounds for the drug targets 
such as GPCR ligand, Ion channel modulator, Kinase 
inhibitor, Nuclear receptor ligand, Protease inhibitor, Protease 
inhibitor and Enzyme inhibitor are evaluated using 
molinspiration tool are listed in the table 3. From the data 
obtained, one can notice that all the six compounds possess 
bioactive score in acceptable ranges. The ADMET analysis in 
early stages of drug discovery is a very crucial since most of 
the compounds fails due to poor pharmacokinetics properties 
and toxicity problems. ADMET properties such as blood 
brain barrier, Caco-2 cell permeability, Human intestinal 
absorption, P-gp substrate, P-gp inhibitor, Ames mutagenicity 
and carcinogenicity were analyzed through computational 
methods and reported in table 4. The result shows that all the 
six compounds are passes the ADMET filters with no 
carcinogenicity and no mutagenicity and all the parameters 
are in acceptable ranges which are the signs of good 
pharmacokinetics profiles. 
The lethal dose 50 (LD 50) values of the six compounds were 
analyzed for the acute toxicity that has administered through 
oral, intraperitoneal, intravenous and subcutaneous on mouse 
/ rat models and also toxicity with reference to different 
organs to check adverse effects on organs and their systems 
are tested and the results are mentioned in table 5. The overall 
results suggested that all the six phytoconstituents had less 
toxic effect on internal tissues and no side-effect were 
observed in the tested dosages.  
The pharmacological effects and biological activities of six 
compounds were analyzed through PASS online server; the 
values of Pa and Pi vary between 0.000 and 1.000. Only 
activities with Pa > Pi are considered as possible for a 
particular compound. If Pa > 0.7, the probability of 
experimental pharmacological action is high and if 0.5 < Pa < 
0.7, probability of experimental pharmacological action is 
less. The tested compounds shows many pharmacological 
activities and mechanism of actions which were represented 
in table 6. 
 
Table 1: Isolated compounds from Flacourtia indica with their 2D and 3D structures. 
 
Sl no Compound 2D Structure 3D Structure 
1 
2-(2-benzoyl- b-D-glucopyranosyloxy)-
7-(1 a,2 a,6a trihydroxy-3-oxocyclohex- 
4-enoyl)-5-hydroxy benzyl alcohol 
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2 poliothrysoside 
  
3 
catechin-[5,6-e]-4b-
(3,4dihydroxyphenyl)dihydro-2(3H)-
pyranone 
  
4 
2-(6-benzoyl-b-D glucopyranosyloxy)-7-
(1a,2 a,6 a-trihydroxy-3-oxocyclohex-4-
enoyl)-5-hydroxybenzyl alcohol 
  
5 chrysoeriol-7-O- b-D-glucopyranoside 
  
6 mururin A 
  
 
Table 2: Lipinski rule of five and Drug-likeness properties prediction using Molsoft online program 
 
Compound 
Molecular 
Formula 
Molecula 
Weight 
Hydrogen 
Bond accepter 
(HBA) 
Hydrogen Bond 
Donator 
( HBD) 
Mol 
LogP 
Number of 
rotatable bonds 
Drug-likeness 
model score 
1 C27 H28 O14 576.15 14 7 -2.21 10 -0.10 
2 C20 H22 O9 406.13 9 5 0.14 7 -0.10 
3 C24 H20 O9 452.11 9 6 2.64 2 1.18 
4 C27 H28 O14 576.15 14 7 -2.07 10 -0.19 
5 C22 H22 O11 462.12 11 6 0.28 5 0.77 
6 C24 H16 O9 448.08 9 5 3.76 1 0.62 
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Fig 1: Drug-likeness model score: -0.10 Fig 2: Drug-likeness model score: -0.10 
 
  
 
Fig 3: Drug-likeness model score: 1.18 Fig 4: Drug-likeness model score: -0.19 
 
   
 
Fig 5: Drug-likeness model score: 0.77 Fig 6: Drug-likeness model score: 0.62 
 
Table 3: Bioactivity scores of Phytocompounds predicted by Molinspiration. 
 
Compond 
GPCR 
ligand 
Ion channel 
modulator 
Kinase 
inhibitor 
Nuclear receptor 
ligand 
Protease 
inhibitor 
Enzyme 
inhibitor 
1 0.09 -0.29 -0.28 0.11 0.14 0.26 
2 0.03 0.01 -0.12 0.12 0.01 0.26 
3 0.25 0.03 -0.17 0.33 0.21 0.32 
4 0.06 -0.26 -0.27 0.13 0.12 0.24 
5 0.05 -0.07 0.14 0.21 -0.06 0.37 
6 0.04 -0.32 -0.08 0.42 -0.15 0.27 
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Table 4: ADME/TOX and pharmacological parameter assessment of phytocompounds predicted using admetSAR toolbox 
 
Compond PlogBBa PCacob logHIAc 
logpGI 
(substrate)d 
logpGI (non-
inhibitor)e 
PlogSf 
AMES 
Toxicity 
Carcin-
ogens 
1 0.6121 0.8530 0.7902 0.7055 0.7135 -1.3448 NT NC 
2 0.5000 0.8892 0.7559 0.5911 0.8115 -0.9489 NT NC 
3 0.6208 0.8591 0.9015 0.6008 0.9421 -3.5109 NT NC 
4 0.5993 0.8427 0.8541 0.7230 0.7362 -1.5114 NT NC 
5 0.9247 0.8957 0.7769 0.6724 0.8575 -2.3177 NT NC 
6 0.6553 0.8641 0.9450 0.5638 0.9077 -3.4816 NT NC 
a-Predicted blood/brain barrier partition coefficient (concern value is −3.0 to 1.0), b-predicted Caco-2 cell permeability in nm/s (acceptable range: 
−1 is poor, 1 is great), c-predicted human intestinal absorption in nm/s (acceptable range: 0 poor, >1 great), d-predicted P-gp substrate in nm/s 
(acceptable range of −5 is poor, 1 is great), e-predicted P-glycoprotein inhibitor in nm/s (accepted range: 0-1), f-predicted aqueous solubility, 
(concern value is −6.5 to –0.5). P-gp: P-glycoprotein, HIA: Human intestinal absorption, ADME: Absorption, distribution, metabolism, 
excretion NT: Non Ames toxic, NC: non carcinogens. 
 
Table 5: LD 50 and probability of health effects of Phytocompounds predicted using ACD/I-Lab 2.0 
 
ADME-TOX Parameters 1 2 3 4 5 6 
LD50 mouse1 (mg/kg, intraperitoneal) 1100 1000 490 900 1100 470 
LD50 mouse1 (mg/kg, oral) 4900 1800 3000 5900 360 2100 
LD50 mouse1 (mg/kg, intravenous) 800 500 69 600 67 110 
LD50 mouse1 (mg/kg, subcutaneous) 2500 1500 140 4200 190 28 
LD50 Rat1 (mg/kg, intraperitoneal) 560 570 1900 440 930 2400 
LD50 Rat1 (mg/kg, oral) 11000 2900 3100 10000 930 3100 
Probability of blood effect2 0.98 0.63 1 0.95 1 0.98 
Probability of cardiovascular system effect2 0.97 0.86 0.97 0.96 0.92 0.99 
Probability of gastrointestinal system effect2 0.96 0.07 0.99 0.97 0.94 1 
Probability of kidney effect2 0.62 0.24 0.86 0.63 0.63 0.9 
Probability of liver effect2 0.71 0.19 0.84 0.72 0.8 0.97 
Probability of lung effect2 0.46 0.42 0.98 0.46 0.52 0.97 
1Estimates LD 50 value in mg/kg after intraperitoneal, oral, intravenous and subcutaneous administration to mice and rat, 2Estimates probability 
of blood, gastrointestinalsystem, kidney, liver and lung effect at therapeutic dose range, 1-6 represents the phytocompounds and the drugs with 
moderate effect on reliability index (>0.5), the drugs with border line effect on reliability index (>0.3, <0.5), LD50: Lethal dose50. 
 
Table 6: Predicted Pa and Pi values of phytocompounds using PASS online server. 
 
Compounds Pa* Pi# 
Predicted Pharmacological 
activity 
pa pi 
Predicted Pharmacological 
Activity 
2
-(
2
-b
en
zo
y
l-
 b
-D
-g
lu
co
p
y
ra
n
o
sy
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x
y
)-
7
-
(1
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,2
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y
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x
o
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h
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o
y
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d
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y
b
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l 
a
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o
h
o
l 
0,928 0,006 
CDP-glycerol glycerophosphotransferase 
inhibitor 
0,799 0,005 Anticarcinogenic 
0,906 0,010 Membrane integrity agonist 0,747 0,003 Monophenol monooxygenase inhibitor 
0,898 0,006 CYP2H substrate 0,752 0,010 
UDP-N-acetylglucosamine 4-epimerase 
inhibitor 
0,862 0,006 Anaphylatoxin receptor antagonist 0,749 0,008 
Mucinaminylserine mucinaminidase 
inhibitor 
0,850 0,007 Antineoplastic 0,751 0,018 Beta-adrenergic receptor kinase inhibitor 
0,850 0,009 Sugar-phosphatase inhibitor 0,751 0,018 G-protein-coupled receptor kinase inhibitor 
0,840 0,004 3-Phytase inhibitor 0,734 0,008 Antiprotozoal (Leishmania) 
0,847 0,011 Benzoate-CoA ligase inhibitor 0,728 0,014 Exoribonuclease II inhibitor 
0,841 0,012 
Alkenylglycerophosphocholine hydrolase 
inhibitor 
0,737 0,025 Membrane permeability inhibitor 
0,830 0,003 Lactase inhibitor 0,710 0,005 Fructan beta-fructosidase inhibitor 
0,818 0,005 Antiinfective    
p
o
li
o
th
ry
so
si
d
e
 
0,973 0,001 Monophenol monooxygenase inhibitor 0,825 0,001 Glucan 1,6-alpha-glucosidase inhibitor 
0,966 0,002 Membrane integrity agonist 0,822 0,001 4-Alpha-glucanotransferase inhibitor 
0,951 0,003 
Alkenylglycerophosphocholine hydrolase 
inhibitor 
0,827 0,006 
NAD(P)+-arginine ADP-ribosyltransferase 
inhibitor 
0,949 0,002 Sugar-phosphatase inhibitor 0,822 0,003 Cyclomaltodextrinase inhibitor 
0,946 0,004 
CDP-glycerol glycerophosphotransferase 
inhibitor 
0,824 0,006 Glucan endo-1,6-beta-glucosidase inhibitor 
0,932 0,002 3-Phytase inhibitor 0,814 0,001 4-Coumarate-CoA ligase inhibitor 
0,933 0,003 Antiinfective 0,814 0,002 Laminaribiose phosphorylase inhibitor 
0,926 0,003 Membrane permeability inhibitor 0,813 0,005 UDP-glucuronosyltransferase substrate 
0,915 0,002 Beta-mannosidase inhibitor 0,808 0,003 Phenylacetate-CoA ligase inhibitor 
0,915 0,002 Mucinaminylserine mucinaminidase inhibitor 0,772 0,009 Membrane integrity antagonist 
0,916 0,003 Anaphylatoxin receptor antagonist 0,771 0,010 Immunostimulant 
0,909 0,002 Fructan beta-fructosidase inhibitor 0,765 0,004 Phosphoinositide 5-phosphatase inhibitor 
0,905 0,003 Exoribonuclease II inhibitor 0,764 0,005 Hepatoprotectant 
0,905 0,005 Benzoate-CoA ligase inhibitor 0,766 0,007 Lipid metabolism regulator 
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0,896 0,003 Cholesterol antagonist 0,761 0,004 Phosphatidylglycerophosphatase inhibitor 
0,894 0,003 
UDP-N-acetylglucosamine 4-epimerase 
inhibitor 
0,761 0,007 Vasoprotector 
0,888 0,003 Antihypercholesterolemic 0,761 0,008 Nucleotide metabolism regulator 
0,885 0,002 Lactase inhibitor 0,753 0,003 H+-exporting ATPase inhibitor 
0,879 0,003 Glucan endo-1,3-beta-D-glucosidase inhibitor 0,751 0,003 Free radical scavenger 
0,876 0,003 Levanase inhibitor 0,749 0,004 N-acylmannosamine kinase inhibitor 
0,877 0,006 Beta-adrenergic receptor kinase inhibitor 0,747 0,005 Antithrombotic 
0,877 0,006 G-protein-coupled receptor kinase inhibitor 0,739 0,004 Mycothiol-S-conjugate amidase inhibitor 
0,864 0,001 Laxative 0,736 0,003 Lactose synthase inhibitor 
0,854 0,003 Anthranilate-CoA ligase inhibitor 0,738 0,006 
IgA-specific metalloendopeptidase 
inhibitor 
0,856 0,005 Fucosterol-epoxide lyase inhibitor 0,731 0,001 Oligo-1,6-glucosidase inhibitor 
0,850 0,002 
Alkenylglycerophosphoethanolamine hydrolase 
inhibitor 
0,734 0,009 Glyceryl-ether monooxygenase inhibitor 
0,838 0,002 Beta-amylase inhibitor 0,731 0,008 Antiprotozoal (Leishmania) 
0,838 0,004 Ribulose-phosphate 3-epimerase inhibitor 0,723 0,002 Glucan 1,4-beta-glucosidase inhibitor 
0,837 0,004 Anticarcinogenic 0,713 0,002 Beta-glucosidase inhibitor 
0,833 0,004 Manganese peroxidase inhibitor 0,712 0,004 D-threo-aldose 1-dehydrogenase inhibitor 
0,837 0,012 CYP2H substrate 0,709 0,004 Histamine release stimulant 
0,827 0,002 Licheninase inhibitor 0,709 0,006 Aspartyltransferase inhibitor 
ca
te
ch
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5
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0,934 0,005 Membrane integrity agonist 0,774 0,005 Antihypercholesterolemic 
0,924 0,004 CYP1A1 substrate 0,771 0,015 Antineoplastic 
0,910 0,005 TP53 expression enhancer 0,748 0,010 Fibrinolytic 
0,892 0,003 UGT1A6 substrate 0,743 0,006 Hepatoprotectant 
0,883 0,016 CYP2C12 substrate 0,731 0,002 Astringent 
0,864 0,003 UGT1A substrate 0,735 0,010 Kinase inhibitor 
0,857 0,005 CYP1A substrate 0,728 0,011 CYP3A4 inducer 
0,836 0,004 UDP-glucuronosyltransferase substrate 0,713 0,004 Free radical scavenger 
0,805 0,003 Pectate lyase inhibitor 0,711 0,005 APOA1 expression enhancer 
0,798 0,004 Antimutagenic 0,713 0,011 CYP3A inducer 
0,798 0,008 CYP2B6 substrate 0,705 0,006 CYP2A11 substrate 
0,787 0,004 Lipid peroxidase inhibitor 0,737 0,040 Mucomembranous protector 
0,780 0,004 HMOX1 expression enhancer 0,702 0,006 CYP2A4 substrate 
0,786 0,013 HIF1A expression inhibitor 0,706 0,014 CYP3A5 substrate 
0,775 0,004 Chemopreventive    
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0,939 0,004 Membrane integrity agonist 0,829 0,014 
Alkenylglycerophosphocholine hydrolase 
inhibitor 
0,933 0,005 
CDP-glycerol glycerophosphotransferase 
inhibitor 
0,821 0,009 Antineoplastic 
0,894 0,004 Anaphylatoxin receptor antagonist 0,810 0,005 Antiinfective 
0,874 0,004 Membrane permeability inhibitor 0,769 0,006 Anticarcinogenic 
0,854 0,003 Monophenol monooxygenase inhibitor 0,747 0,004 H+-exporting ATPase inhibitor 
0,851 0,010 Benzoate-CoA ligase inhibitor 0,744 0,011 UDP-glucuronosyltransferase substrate 
0,836 0,003 Lactase inhibitor 0,732 0,009 
Mucinaminylserine mucinaminidase 
inhibitor 
0,842 0,011 CYP2H substrate 0,715 0,014 Antiinflammatory 
0,840 0,011 Sugar-phosphatase inhibitor 0,710 0,016 Exoribonuclease II inhibitor 
0,833 0,004 3-Phytase inhibitor    
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0,982 0,001 Monophenol monooxygenase inhibitor 0,834 0,006 
NAD(P)+-arginine ADP-ribosyltransferase 
inhibitor 
0,976 0,001 Membrane permeability inhibitor 0,829 0,005 CYP3A inducer 
0,976 0,002 Membrane integrity agonist 0,830 0,009 Antineoplastic 
0,974 0,001 Cardioprotectant 0,825 0,004 UGT1A9 substrate 
0,973 0,001 Vasoprotector 0,810 0,001 Alpha glucosidase inhibitor 
0,972 0,001 Free radical scavenger 0,821 0,013 Sugar-phosphatase inhibitor 
0,971 0,001 Hemostatic 0,818 0,017 Chlordecone reductase inhibitor 
0,959 0,000 Beta-N-acetylhexosaminidase inhibitor 0,807 0,006 Membrane integrity antagonist 
0,956 0,003 TP53 expression enhancer 0,803 0,003 Antioxidant 
0,951 0,002 Chemopreventive 0,795 0,001 Skin whitener 
0,948 0,002 Hepatoprotectant 0,793 0,002 CYP2E1 inducer 
0,945 0,002 CYP1A inducer 0,796 0,006 Kinase inhibitor 
0,943 0,002 Anticarcinogenic 0,792 0,003 Mediator release inhibitor 
0,943 0,002 Lipid peroxidase inhibitor 0,784 0,004 3-Phytase inhibitor 
0,940 0,001 NADPH oxidase inhibitor 0,782 0,005 Antiinfective 
0,941 0,003 Caspase 3 stimulant 0,777 0,004 UGT1A1 substrate 
0,940 0,003 Anaphylatoxin receptor antagonist 0,767 0,002 Caspase 8 stimulant 
0,940 0,003 UDP-glucuronosyltransferase substrate 0,770 0,010 Apoptosis agonist 
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0,930 0,002 Antiprotozoal (Leishmania) 0,763 0,007 
Mucinaminylserine mucinaminidase 
inhibitor 
0,929 0,005 
CDP-glycerol glycerophosphotransferase 
inhibitor 
0,754 0,002 Sweetener 
0,923 0,003 Antihypercholesterolemic 0,756 0,004 Mycothiol-S-conjugate amidase inhibitor 
0,920 0,001 CYP1A1 inducer 0,760 0,010 2-Dehydropantoate 2-reductase inhibitor 
0,913 0,001 4-Coumarate-CoA ligase inhibitor 0,772 0,022 
Alkenylglycerophosphocholine hydrolase 
inhibitor 
0,895 0,001 Histamine release stimulant 0,743 0,005 Cyclic AMP phosphodiesterase inhibitor 
0,893 0,001 CYP2C9 inducer 0,745 0,010 Oxidoreductase inhibitor 
0,893 0,001 Laxative 0,736 0,006 Vasodilator 
0,892 0,000 Capillary fragility treatment 0,729 0,002 Glucan 1,6-alpha-glucosidase inhibitor 
0,897 0,006 HIF1A expression inhibitor 0,733 0,008 Radioprotector 
0,887 0,003 UGT1A substrate 0,750 0,026 CYP2H substrate 
0,881 0,001 UGT1A7 substrate 0,727 0,004 Beta glucuronidase inhibitor 
0,881 0,003 Sulfotransferase substrate 0,725 0,010 Nucleotide metabolism regulator 
0,874 0,002 Proliferative diseases treatment 0,719 0,005 Antiviral (Influenza) 
0,871 0,001 Xanthine dehydrogenase inhibitor 0,719 0,007 Histidine kinase inhibitor 
0,863 0,004 CYP3A4 inducer 0,715 0,004 Choleretic 
0,845 0,003 Lactase inhibitor 0,706 0,007 HMOX1 expression enhancer 
0,847 0,005 Cytostatic 0,707 0,009 Antifungal 
0,852 0,010 Benzoate-CoA ligase inhibitor 0,701 0,004 Antitussive 
0,833 0,001 Aryl hydrocarbon receptor agonist    
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0,934 0,005 Membrane integrity agonist 0,808 0,006 CYP1A substrate 
0,925 0,004 TP53 expression enhancer 0,781 0,003 Pectate lyase inhibitor 
0,900 0,002 Antimutagenic 0,777 0,004 CYP2A11 substrate 
0,873 0,004 UGT1A6 substrate 0,777 0,004 General pump inhibitor 
0,861 0,003 Histidine kinase inhibitor 0,747 0,004 Histamine release inhibitor 
0,861 0,003 UGT1A substrate 0,745 0,005 HMOX1 expression enhancer 
0,861 0,004 CYP1A1 substrate 0,739 0,006 Hepatoprotectant 
0,843 0,003 Chemopreventive 0,731 0,004 Free radical scavenger 
0,841 0,004 UDP-glucuronosyltransferase substrate 0,730 0,004 CYP1A inhibitor 
0,841 0,008 Antineoplastic 0,726 0,005 UGT1A1 substrate 
0,855 0,023 CYP2C12 substrate 0,714 0,005 Antineoplastic (breast cancer) 
0,821 0,004 Sulfotransferase substrate 0,705 0,006 CYP2A4 substrate 
0,822 0,010 HIF1A expression inhibitor    
*probability of activity, # probability of inactivity 
 
Conclusion 
The ethnobotanicals have been regularly used since the 
ancient civilization as ethnomedicine’s for various illness 
from simple cold to threat full diseases like cancer etc., As 
recent report of WHO testifies that about 80% of the world’s 
population relies on the phytopharmaceuticals for the 
treatment of various common diseases. In the era of many 
emerging and re-emerging diseases phytochemical 
compounds derived from plant sources have great 
pharmacological importance. The cure for a particular disease 
is addressed by a potent lead molecule for their biological 
activities against the disease therefore; computational 
approach has led to the identification of drug target and in the 
prediction of novel leads. In present study we have analyzed 
six isolated compounds from Flacourtia indica through 
QSAR approach computationally; it is interesting to reveal 
that all the six compounds were nontoxic and showing good 
ADMET profiles and high drug likeness properties with many 
biological activities and mechanism of actions. Screening of 
bioactive compounds from plants as source, has restored 
health benefits due to their biological activities, thus in the 
present study phytocompounds from Flacoutia indica 
provides ethnomedical evidences as potential 
phytopharmaceuticals, however further In vitro and In vivo 
analysis of each compound for various pharmacological 
benefits can be carried out for the discovery of novel drug 
compounds.  
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